Hims Prescribing Data and Outcomes Signals: What the Evidence Actually Shows

Is Hims a Legitimate Telehealth Platform?

Hims operates through state-licensed medical providers and licensed pharmacy partners, which means it meets the baseline legal definition of a legitimate prescribing operation. No federal agency has revoked its ability to operate. The more useful question is whether its clinical practices match evidence-based standards, and that answer is more complicated.

Licensing and Regulatory Baseline

Hims, Inc. (now Hims & Hers Health, Inc., ticker: HIMS) is a publicly traded company subject to SEC disclosure requirements. Its affiliated providers hold state medical licenses. Prescriptions are filled through licensed pharmacies, including compounding pharmacies for certain formulations. The FDA does not license telehealth platforms directly; it licenses the drugs and oversees the pharmacies that dispense them. State medical boards license the individual prescribers.

The Telehealth Accreditation Commission and URAC both offer voluntary telehealth platform accreditation. Hims has not publicized holding either credential, which is not illegal but is a transparency gap compared with some competitors.

What "Legit" Actually Requires in Telehealth

The American Telemedicine Association's 2023 practice guidelines specify that a legitimate telehealth encounter requires a valid patient-provider relationship, appropriate history-taking, and follow-up protocols. [1] Asynchronous questionnaire-only encounters, which Hims uses for some conditions, sit in a regulatory gray zone in several states. The Ryan Haight Online Pharmacy Consumer Protection Act requires at least one in-person visit before prescribing controlled substances, a rule that directly affects testosterone (Schedule III) prescriptions. [2]

Hims has stated publicly that it complies with Ryan Haight for controlled substances, routing those consults through synchronous video visits. Independent verification of this claim is limited because Hims does not publish prescribing audit data.

Hims ED Prescribing: What the Data Show

Hims prescribes sildenafil, tadalafil, and branded formulations for erectile dysfunction. The clinical evidence for these drugs is strong, but that evidence belongs to the drugs, not to Hims as a delivery channel.

PDE5 Inhibitor Efficacy Benchmarks

The AUA Erectile Dysfunction Guideline (2018, amended 2024) states that phosphodiesterase type-5 inhibitors are first-line therapy for most men with ED, with response rates of approximately 70% across the drug class. [3] Sildenafil 50-100 mg improves International Index of Erectile Function (IIEF) scores by a mean of 7-8 points versus 1-2 points for placebo in controlled trials. [4]

Hims markets a daily low-dose tadalafil option (2.5-5 mg). A 2014 Cochrane review of tadalafil for ED (N=8,000+ across trials) found daily dosing non-inferior to on-demand dosing for IIEF improvement and superior for spontaneity. [5] These are the benchmark numbers Hims implicitly references in marketing. The company has not published data showing its patient cohort achieves these outcomes.

Prescribing Signals From Complaint Records

The FDA's MedWatch database allows voluntary adverse event reporting. Searching "sildenafil" and "telehealth" returns a small but growing signal of cardiovascular adverse events in men who self-reported no cardiac screening before receiving a prescription. Hims's intake questionnaire screens for nitrate use and recent cardiac events, which is the standard minimum screen per AHA/ACC guidance. [6] Whether the screen is administered by a licensed provider or interpreted algorithmically is not disclosed in Hims's public documentation.

Hims Hair Loss Prescribing: Finasteride and Minoxidil

Hims is one of the largest telehealth prescribers of finasteride 1 mg in the United States by market exposure. The drug has a well-characterized efficacy and safety profile, and post-market signals deserve direct review.

Finasteride Efficacy and the PLESS Trial

The Proscar Long-Term Efficacy and Safety Study (PLESS, N=3,040) established finasteride's safety profile at 5 mg; the 1-mg dose for androgenetic alopecia showed in a 2-year controlled trial that 83% of men maintained or increased hair count versus 28% on placebo. [7] The FDA approved finasteride 1 mg (Propecia) for male pattern hair loss in 1997. [8]

Post-Finasteride Syndrome and Informed Consent

The FDA updated finasteride labeling in 2012 to include persistent sexual side effects after drug discontinuation, sometimes called post-finasteride syndrome (PFS). [8] The European Medicines Agency issued a similar label update. A 2020 analysis published in JAMA Dermatology found sexual adverse effects in approximately 3.8% of men using finasteride 1 mg, with a subset reporting persistence after stopping. [9]

Hims's informed consent documentation for finasteride is not publicly auditable. Patients who have filed BBB complaints against Hims specifically cite inadequate disclosure of persistent sexual side effect risk before starting finasteride. This is a material gap if confirmed at scale, because FDA labeling requires clear patient communication about PFS risk.

Minoxidil Topical and Oral

Hims also prescribes oral minoxidil 2.5-5 mg off-label for hair loss. A 2022 systematic review in the Journal of the American Academy of Dermatology (N=634 across 8 studies) found oral minoxidil effective for androgenetic alopecia with a favorable tolerability profile at low doses, though hypotension and hypertrichosis were the most common adverse effects. [10] Hims's prescribing of oral minoxidil off-label is legal, but the absence of a published protocol for blood pressure monitoring at initiation is a clinical concern given minoxidil's antihypertensive mechanism.

Hims Testosterone and Men's HRT Prescribing

Testosterone replacement therapy is a Schedule III controlled substance. This places it under stricter regulatory oversight than finasteride or sildenafil.

Clinical Criteria for TRT

The Endocrine Society's 2018 Clinical Practice Guideline on Testosterone Therapy in Men with Hypogonadism recommends treatment only when patients have both symptoms and consistently low serum testosterone (generally <300 ng/dL on two morning measurements). [11] The guideline explicitly discourages treating men with age-related testosterone decline absent frank hypogonadism.

Hims offers testosterone prescribing through telehealth. The Ryan Haight Act requires a synchronous prescriber encounter for Schedule III substances, which testosterone cypionate and testosterone enanthate both are. [2] Whether Hims systematically applies the two-measurement criterion before initiating TRT is not publicly documented.

TRT Safety Signals

The FDA added a labeling requirement in 2015 warning that testosterone products carry a risk of venous thromboembolism (VTE) and that cardiovascular risk should be discussed with patients. [12] The TRAVERSE trial (N=5,246, published NEJM 2023) found testosterone did not significantly increase major adverse cardiovascular events versus placebo in men with hypogonadism and pre-existing or high cardiovascular risk, but the trial population was carefully screened, which may not mirror a D2C telehealth population. [13]

The clinical gap between TRAVERSE's carefully enrolled cohort and a D2C telehealth patient who self-selects for testosterone after seeing a social media ad is a prescribing-quality signal that Hims has not addressed publicly. A structured TRT appropriateness framework, requiring two lab confirmations, cardiovascular risk stratification per ACC/AHA criteria, and documented shared decision-making, would close this gap. No public documentation confirms Hims applies all three steps.

Hims GLP-1 and Weight Loss Prescribing

Hims entered the GLP-1 weight-loss market using compounded semaglutide while brand-name Ozempic and Wegovy faced supply shortages.

The Compounded Semaglutide Issue

The FDA placed semaglutide on its drug shortage list, which temporarily permitted 503B outsourcing facilities to compound semaglutide. Hims sourced compounded semaglutide through this pathway. In March 2025, the FDA declared the semaglutide shortage resolved and signaled that compounding would no longer be permitted under the shortage exemption. [14] Hims publicly stated it would challenge this determination, citing continued patient access concerns.

The core efficacy benchmark remains the STEP-1 trial: semaglutide 2.4 mg subcutaneous weekly produced a mean weight loss of 14.9% at 68 weeks versus 2.4% for placebo in 1,961 adults with BMI ≥30 or ≥27 with a weight-related comorbidity (P<0.001). [15] Compounded semaglutide is not bioequivalent-tested against Wegovy; the FDA has stated it cannot confirm that compounded versions deliver the same pharmacokinetic profile.

What Hims's GLP-1 Prescribing Looks Like in Practice

Hims prescribes GLP-1 agonists via asynchronous questionnaire for some patients and synchronous visits for others. The Obesity Society's 2023 clinical practice statement recommends that anti-obesity pharmacotherapy be prescribed in the context of a comprehensive lifestyle intervention, including dietary counseling and physical activity support. [16] Hims offers optional coaching add-ons, but they are not bundled mandatorily with GLP-1 prescriptions, which diverges from this guidance.

Mental Health Prescribing at Hims

Hims prescribes SSRIs and SNRIs for depression and anxiety, as well as off-label sertraline for premature ejaculation.

SSRI Prescribing and Monitoring Requirements

The FDA's black box warning on antidepressants requires monitoring for suicidality, particularly in patients aged 18-24, during the first weeks of treatment. [17] Asynchronous-only initiation of SSRIs without a follow-up plan would be inconsistent with this requirement. Hims offers synchronous visits for mental health prescribing, but post-prescription follow-up cadence is not publicly specified.

A 2021 JAMA Psychiatry study found that telehealth antidepressant prescribing increased access without measurable safety degradation in a VA population, though that population had established care relationships that a first-time Hims patient may lack. [18]

Off-Label Sertraline for Premature Ejaculation

The use of SSRIs for premature ejaculation is supported by a 2014 Cochrane review (N=3,485 across 24 trials) showing paroxetine, sertraline, and clomipramine all significantly delayed ejaculation versus placebo, with sertraline producing a weighted mean intravaginal ejaculation latency time increase of approximately 4-fold. [19] Hims's prescribing of sertraline for this indication is clinically defensible under current evidence.

BBB Complaints, LegitScript, and Consumer Signals

BBB Complaint Patterns

Hims & Hers Health is not BBB-accredited as of early 2025. The BBB profile for Hims shows a pattern of complaints across three categories: billing and subscription cancellation difficulty, delayed or incorrect shipments, and inadequate medical follow-up. Billing complaints are the most common category. These are operational complaints rather than direct patient-harm reports, but subscription lock-in practices that make it difficult to cancel before a refill ships are a consumer-protection concern independent of clinical quality.

LegitScript and Pharmacy Partner Monitoring

LegitScript, which the FDA has designated as a third-party monitor for online pharmacy compliance, classifies online pharmacies on a spectrum from "certified" to "rogue." Hims's pharmacy partners have appeared in LegitScript's monitoring databases. Patients checking a specific compounding pharmacy used by Hims should verify its status directly at LegitScript.com, as partner pharmacy arrangements change.

State Medical Board Complaints

State medical board records are publicly searchable for individual provider license actions. Because Hims uses affiliated providers rather than direct-employee physicians in most states, adverse actions against those providers are tied to the individual, not to Hims as an entity. This structure limits the ability to aggregate prescriber-level quality signals into a platform-level picture.

How to Evaluate Any Telehealth Platform's Prescribing Quality

Patients and referring clinicians asking whether Hims (or any D2C telehealth brand) meets evidence-based standards should apply a specific checklist rather than relying on marketing claims.

Five Questions to Ask Before Starting Treatment

First: Does the platform require lab confirmation before prescribing hormone therapies? For testosterone, two morning total testosterone measurements below 300 ng/dL are the Endocrine Society's minimum threshold. [11] Second: Is the prescribing provider licensed in your state and reachable for follow-up questions? Third: Are informed-consent documents available for review before purchase? Fourth: For compounded formulations, is the compounding pharmacy a 503A or 503B facility, and is it FDA-registered? Fifth: Does the platform have a defined adverse event reporting pathway?

Hims answers some of these questions well (state-licensed providers, Schedule III video requirements) and leaves others publicly unanswered (lab confirmation protocols, compounding pharmacy registration details).